Spinal StenosisNCT01892878
Clinical Outcome and Fusion Results Using the VerteLoc® Facet Fixation Device
A study testing VerteLoc in people with Spinal Stenosis, run by VG Innovations, LLC at 1 site in United States.
Trial summary
The purpose of this clinical study is to evaluate fusion of the facet joints in a prospective cohort of patients utilizing the VerteLoc facet fixation device in patients receiving lumbar laminectomy (L1-S1), without ancillary stabilization devices such as pedicle and transfacet screws. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Spinal Stenosis
- What is being tested?
- VerteLoc
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- 1 siteUnited States
- Study dates
- Jul 2013to 1 Jan 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Have provided consent for research by signing the Institutional Review Board approved Informed Consent;
- Have given appropriate operative consent for a decompressive lumbar (L1-S1) laminectomy procedure as standard of care;
- Are skeletally mature, and are at least 18 years of age;
- If female, are not pregnant;
- Agree to adhere to post-surgical medically prescribed activity limitations and/or physical rehabilitation.
Who cannot join
- Previous surgery at the target or adjacent vertebral levels;
- More than two intervertebral levels to be treated by the laminectomy procedure;
- Found to be inappropriate candidates for facet fixation using the VerteLoc system;
- Require additional and/or other surgical technique and/or approach to the laminectomy at the index level(s), which may in the opinion of the Primary Investigator confound measurement of outcome variables;
- Has a medical disorder or is receiving medications that would be expected to interfere with osteogeneses,
- Active malignancy or patient with a history of any malignancy (except non-melanoma skin cancer) with recurrence within 5 years of surgery;
Show all 11Show fewer
- Active local or systemic infection or history of local or systemic infection, immune-deficiency, uncontrolled medical conditions, which in the opinion of the Investigator may increase patient risk or confound fusion results;
- BMI >40% ;
- History of tobacco smoking within the past 6 months;
- Has a history of alcoholism, medication or drug abuse, psychosis, is a prisoner, and/or has a personality disorder, poor motivation, emotional or intellectual issues that would likely make the patient unreliable for participation in the study;
- Are participating in any other clinical trial.
Trial locations and contacts
1 site in 1 country.
United States1 site
Genesys Regional Medical Center
Grand Blanc, Michigan, 48439
About this study
Official title: A Prospective, Single Arm Clinical Trial Evaluating Clinical Outcome and Fusion Results Using the VerteLoc® Facet Fixation Device
The purpose of this clinical study is to evaluate fusion of the facet joints in a prospective cohort of patients utilizing the VerteLoc facet fixation device in patients receiving lumbar laminectomy (L1-S1), without ancillary stabilization devices such as pedicle and transfacet screws.
Read the detailed description
Study Design: Non-randomized, prospective, single arm clinical trial
Patient Population and Sample Size: Patients (n=25) from up to 2 clinical site, who have been medically evaluated, found appropriate for, and have agreed to treatment by lumbar decompressive laminectomy and facet fixation, including unilateral and/or bilateral posterolateral fusion according to accepted medical standards.
Objectives:
The primary objective of this study is to:
- Evaluate the fusion status of facet joints following laminectomy and facet fixation using the VerteLoc system in combination with unilateral and/or bilateral posterolateral fusion.
- Subject success / Clinical outcome: Evaluate the reduction in baseline VAS back pain score at 2-3 weeks, 3 months, and 12 months.
The secondary objectives of this study are to:
- Explore the effect of preoperative bone density on facet fusion status;
- Assess the ease of use of the VerteLoc system;
- Record operative time using the VerteLoc system;
- Monitor the occurrence of adverse events related or possibly related to the use of the VerteLoc system;
- Monitor the occurrence of subsequent surgical intervention at the target level(s).
- Subject success/Clinical outcome (Assess additional improvement criteria)
- Evaluate Fusion rate in relations to DEXA value
Inclusion Criteria: Candidates must meet ALL of the following:
- Have provided consent for research by signing the Institutional Review Board approved Informed Consent;
- Have given appropriate operative consent for a decompressive lumbar (L1-S1) laminectomy procedure as standard of care;
- Are skeletally mature, and are at least 18 years of age;
- If female, are not pregnant;
- Agree to adhere to post-surgical medically prescribed activity limitations and/or physical rehabilitation.
Exclusion Criteria:
- Previous surgery at the target or adjacent vertebral levels;
- More than two intervertebral levels to be treated by the laminectomy procedure;
- Found to be inappropriate candidates for facet fixation using the VerteLoc system;
- Require additional and/or other surgical technique and/or approach to the laminectomy at the index level(s), which may in the opinion of the Primary Investigator confound measurement of outcome variables;
- Has a medical disorder or is receiving medications that would be expected to interfere with osteogeneses,
- Active malignancy or patient with a history of any malignancy (except non-melanoma skin cancer) with recurrence within 5 years of surgery;
- Active local or systemic infection or history of local or systemic infection, immune-deficiency, uncontrolled medical conditions, which in the opinion of the Investigator may increase patient risk or confound fusion results;
- BMI >40% ;
- History of tobacco smoking within the past 6 months;
- Has a history of alcoholism, medication or drug abuse, psychosis, is a prisoner, and/or has a personality disorder, poor motivation, emotional or intellectual issues that would likely make the patient unreliable for participation in the study;
- Are participating in any other clinical trial. Study Duration : 12 months
Study Outcomes:
The primary study outcomes of this study are:
- Fusion grade at 12 month follow-up using CT scans with a grading system based on:
- Complete fusion;
- Partial fusion;
- No fusion;
- Subject success / Clinical outcome:
Evaluate the reduction in baseline VAS back pain score at:
- 2-3 weeks
- 3 months
- 12 months.
The secondary outcomes of this study are:
- Statistical correlation of DEXA scan bone mass density score to CT and radiographic fusion status;
- Surgeon opinion of "ease of use" utilizing the VerteLoc system (0-10);
- Operative time (minutes) from surgical access to completion of device placement
- Occurrence and prevalence of adverse events related or possibly related to the use of the VerteLoc System;
- Occurrence of subsequent surgical intervention at the target level(s).
Study Assessments
- Intraoperative: Post-placement radiograph;
- 12 months: A/P and lateral flexion and extension lumbar radiograph and lumbar CT scan.
Statistical Analysis
- Student t-tests
- Conditions
- Spinal Stenosis
- Being tested
- VerteLoc
- Medical subject headings
- Spinal Stenosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VerteLocProcedure or surgery
Single Arm
| Study group | Role | What they receive |
|---|---|---|
| Single Arm Study | Other | All patients will receive treatment Receives: Procedure: VerteLoc |
What is being measured
The primary outcome is the main question the study is designed to answer.
Fusion grade at 12 month follow-up using CT scans
Fusion grade at 12 month follow-up using CT scans with a grading system based on:
- Complete fusion;
- Partial fusion;
- No fusion;
Measured: 12 months
Secondary outcomes (1)
Subject success / Clinical outcome
Subject success / Clinical outcome:
Evaluate the reduction in baseline VAS back pain score.
Measured: 2-3 weeks, 3 months and 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jul 2013 (estimated)
- Study startJul 2013
- Primary completionJul 2015 (estimated)
- Study completion1 Jan 2016 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Spinal StenosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- VG Innovations, LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Lisa Guyot, MD, Principal investigator, Ascension Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01892878
- Sponsor's protocol ID
- VGI-002
- Status last verified
- Jul 2013
- First submitted
- 1 Jul 2013
- Last updated
- 16 Mar 2018
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Mar 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Single Arm Clinical Trial Evaluating Clinical Outcome and Fusion Results Using the VerteLoc® Facet Fixation Device
- ClinicalTrials.gov ID
- NCT01892878
- Acronym / sponsor ID
- VGI-002
- Conditions
- Spinal Stenosis
- Study type
- Interventional
- Recruitment status
- Withdrawn
- Enrolment
- 0 participants (actual)
- Lead sponsor
- VG Innovations, LLCIndustry (pharma, biotech, devices)
- Study start
- Jul 2013
- Primary completion
- Jul 2015 (estimated)
- Study completion
- 1 Jan 2016 (estimated)
- First posted
- 8 Jul 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this clinical study is to evaluate fusion of the facet joints in a prospective cohort of patients utilizing the VerteLoc facet fixation device in patients receiving lumbar laminectomy (L1-S1), without ancillary stabilization devices such as pedicle and transfacet screws.
Detailed description
Study Design: Non-randomized, prospective, single arm clinical trial
Patient Population and Sample Size: Patients (n=25) from up to 2 clinical site, who have been medically evaluated, found appropriate for, and have agreed to treatment by lumbar decompressive laminectomy and facet fixation, including unilateral and/or bilateral posterolateral fusion according to accepted medical standards.
Objectives:
The primary objective of this study is to:
- Evaluate the fusion status of facet joints following laminectomy and facet fixation using the VerteLoc system in combination with unilateral and/or bilateral posterolateral fusion.
- Subject success / Clinical outcome: Evaluate the reduction in baseline VAS back pain score at 2-3 weeks, 3 months, and 12 months.
The secondary objectives of this study are to:
- Explore the effect of preoperative bone density on facet fusion status;
- Assess the ease of use of the VerteLoc system;
- Record operative time using the VerteLoc system;
- Monitor the occurrence of adverse events related or possibly related to the use of the VerteLoc system;
- Monitor the occurrence of subsequent surgical intervention at the target level(s).
- Subject success/Clinical outcome (Assess additional improvement criteria)
- Evaluate Fusion rate in relations to DEXA value
Inclusion Criteria: Candidates must meet ALL of the following:
- Have provided consent for research by signing the Institutional Review Board approved Informed Consent;
- Have given appropriate operative consent for a decompressive lumbar (L1-S1) laminectomy procedure as standard of care;
- Are skeletally mature, and are at least 18 years of age;
- If female, are not pregnant;
- Agree to adhere to post-surgical medically prescribed activity limitations and/or physical rehabilitation.
Exclusion Criteria:
- Previous surgery at the target or adjacent vertebral levels;
- More than two intervertebral levels to be treated by the laminectomy procedure;
- Found to be inappropriate candidates for facet fixation using the VerteLoc system;
- Require additional and/or other surgical technique and/or approach to the laminectomy at the index level(s), which may in the opinion of the Primary Investigator confound measurement of outcome variables;
- Has a medical disorder or is receiving medications that would be expected to interfere with osteogeneses,
- Active malignancy or patient with a history of any malignancy (except non-melanoma skin cancer) with recurrence within 5 years of surgery;
- Active local or systemic infection or history of local or systemic infection, immune-deficiency, uncontrolled medical conditions, which in the opinion of the Investigator may increase patient risk or confound fusion results;
- BMI >40% ;
- History of tobacco smoking within the past 6 months;
- Has a history of alcoholism, medication or drug abuse, psychosis, is a prisoner, and/or has a personality disorder, poor motivation, emotional or intellectual issues that would likely make the patient unreliable for participation in the study;
- Are participating in any other clinical trial. Study Duration : 12 months
Study Outcomes:
The primary study outcomes of this study are:
- Fusion grade at 12 month follow-up using CT scans with a grading system based on:
- Complete fusion;
- Partial fusion;
- No fusion;
- Subject success / Clinical outcome:
Evaluate the reduction in baseline VAS back pain score at:
- 2-3 weeks
- 3 months
- 12 months.
The secondary outcomes of this study are:
- Statistical correlation of DEXA scan bone mass density score to CT and radiographic fusion status;
- Surgeon opinion of "ease of use" utilizing the VerteLoc system (0-10);
- Operative time (minutes) from surgical access to completion of device placement
- Occurrence and prevalence of adverse events related or possibly related to the use of the VerteLoc System;
- Occurrence of subsequent surgical intervention at the target level(s).
Study Assessments
- Intraoperative: Post-placement radiograph;
- 12 months: A/P and lateral flexion and extension lumbar radiograph and lumbar CT scan.
Statistical Analysis
- Student t-tests
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Single Arm Study | Other | Procedure: VerteLocAll patients will receive treatment |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Have provided consent for research by signing the Institutional Review Board approved Informed Consent;
- Have given appropriate operative consent for a decompressive lumbar (L1-S1) laminectomy procedure as standard of care;
- Are skeletally mature, and are at least 18 years of age;
- If female, are not pregnant;
- Agree to adhere to post-surgical medically prescribed activity limitations and/or physical rehabilitation.
Key exclusion criteria (11 listed)
- Previous surgery at the target or adjacent vertebral levels;
- More than two intervertebral levels to be treated by the laminectomy procedure;
- Found to be inappropriate candidates for facet fixation using the VerteLoc system;
- Require additional and/or other surgical technique and/or approach to the laminectomy at the index level(s), which may in the opinion of the Primary Investigator confound measurement of outcome variables;
- Has a medical disorder or is receiving medications that would be expected to interfere with osteogeneses,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| VerteLocSingle Arm | Procedure or surgery | Single Arm Study |
Primary outcome
Fusion grade at 12 month follow-up using CT scans
Time frame: 12 months
Fusion grade at 12 month follow-up using CT scans with a grading system based on: 1. Complete fusion; 2. Partial fusion; 3. No fusion;
1 secondary outcome
Subject success / Clinical outcome
Time frame: 2-3 weeks, 3 months and 12 months
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Mar 2018.
Related trials for Spinal Stenosis
Not yet recruitingObservational study
Foraminal Imaging and Symptoms in Single-Level Degenerative Lumbar Stenosis
Degenerative Lumbar Spinal Stenosis, Lumbar Foraminal Stenosis
Recruiting
Post-Market Clinical Study of Functional Motion Outcomes in Subjects Treated With the Minuteman Device
Degenerative Conditions of the Lumbar Spine, Lumbar Spinal Stenosis
RecruitingObservational study
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Lumbar Spinal Stenosis
Active, not recruitingPhase 3
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy
Melanoma, Ovarian Cancer
RecruitingObservational study
Thoracic-Lumbar Arthrodesis- Implanet Jazz
Spondylolisthesis, Spinal Stenosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lisa Guyot, MD principal investigator
Ascension Health
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing VerteLoc in people with Spinal Stenosis, run by VG Innovations, LLC at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 16 Mar 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Fusion grade at 12 month follow-up using CT scans (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Mar 2018.